Delpharm a leading Contract Development and Manufacturing Organization (CDMO) has announced a landmark agreement with the Government of Canada to modernize its injectable manufacturing facility in Boucherville, Quebec. This collaboration ensures the long-term sustainability of the Boucherville site securing Canada’s local supply chain for sterile injectable medicines and bolstering the country’s healthcare autonomy.
Strengthening Canada’s Healthcare Supply Chain
The Boucherville facility plays a critical role in Canada’s healthcare system producing 20 of the 100 essential medicines identified as vital for patient care. These include generic injectable medications used in surgeries and intensive care units across the country. By modernizing the plant, Delpharm aims to enhance its production capacity and ensure a stable supply of these life-saving drugs, even amid global supply chain disruptions.
The modernization plan is backed by a significant investment of over 128 million euros ($140 million) and is scheduled to continue until 2031. The project includes expanding the site, installing a new filling line, and upgrading 95% of the existing equipment to meet the latest Health Canada standards. This transformation will not only improve efficiency but also ensure compliance with stringent regulatory requirements.
A 10-Year Partnership with Sandoz
A key component of this initiative is the 10-year agreement between Delpharm and Sandoz a global leader in generic pharmaceuticals. This partnership ensures a reliable supply of critical medicines for Canadians, reinforcing the country’s ability to meet healthcare demands independently.
Mathieu Grondin, Site Director at Delpharm, emphasized the importance of this collaboration. “This transformation will elevate our site to world-class status, significantly increasing our production capacity and competitiveness. The injectable medications we produce are essential for nearly all surgeries and intensive care treatments in Canada. This partnership with Sandoz is a cornerstone of the country’s healthcare system,” he said.
Grondin also acknowledged the support of the federal government and the trust placed in Delpharm by Sandoz. “This success is a testament to our joint commitment. Without this collaboration, such a transformative project would not have been possible,” he added.
Preserving Jobs and Enhancing Expertise
The modernization plan will preserve over 500 highly skilled jobs in Quebec contributing to the local economy and workforce development. Additionally, the upgraded facility will solidify Delpharm’s position as a center of excellence for sterile and biological products in the North American market.
Stéphane Lepeu, Chief Commercial Officer at Delpharm, highlighted the strategic importance of the Boucherville site. “This investment enhances the appeal of our Boucherville facility, which is recognized as our hub for sterile and biological product expertise in North America. It underscores our commitment to delivering high-quality, life-saving medications to patients across the region,” he said.
A Step Toward Healthcare Resilience
The modernization of Delpharm’s Boucherville facility represents a significant step toward strengthening Canada’s healthcare resilience. By investing in advanced manufacturing capabilities and fostering strategic partnerships, Delpharm is ensuring that Canadians have access to essential medicines, even in times of global uncertainty.
This initiative not only supports the local economy but also reinforces Canada’s position as a leader in pharmaceutical innovation and self-sufficiency. As the project progresses, Delpharm’s Boucherville site will continue to play a vital role in safeguarding the health and well-being of Canadians.
